ERLEADA (apalutamide)

ERLEADA (apalutamide)

SELF ADMINISTRATION

Indications for Prior Authorization:

• Treatment of patients with non-metastatic castration-resistant prostate cancer (NM-CRPC)

Patients must meet the following criteria for the indication(s) above:

• Diagnosis of non-metastatic, castration-resistant prostate cancer (NM-CRPC), AND
• Prescribed by or in consultation with an oncologist or urologist, AND
• Patient will receive a gonadotropin-releasing hormone (GnRH) analog concurrently or has had bilateral orchiectomy

Dosing:

• 240 mg (four 60mg tablets) once daily
• Bone support should be used in patients receiving Erleada

Approval:

• 1 year